Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial

OBJECTIVE: GAD formulated in aluminum hydroxide (GAD-alum) has previously been shown to induce preservation of residual insulin secretion in recent-onset type 1 diabetes, but recent phase II and III GAD-alum trials failed to reach primary outcomes. The European phase III study was therefore closed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Axelsson, Stina, Chéramy, Mikael, Åkerman, Linda, Pihl, Mikael, Ludvigsson, Johnny, Casas, Rosaura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816912/
https://www.ncbi.nlm.nih.gov/pubmed/23863909
http://dx.doi.org/10.2337/dc12-2251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816912/
https://www.ncbi.nlm.nih.gov/pubmed/23863909
http://dx.doi.org/10.2337/dc12-2251

Ejemplares similares